TNF and inflammatory bowel disease: The mainstay of current IBD therapy has been shown to positively affect metabolic impairments as well, as anti-TNF-α treatment decreases LDL and increases HDL cholesterol levels, reduces insulin resistance, improves endothelial dysfunction, and reduces cardiovascular risk [61].